Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 [mipomersen sodium] in Subjects With Familial Hypercholesterolemia

Next Previous
Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 [mipomersen sodium] in Subjects With Familial Hypercholesterolemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation

Most Recent Events

  • 24 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 02 Sep 2014 Results of a retrospective analysis including patients with both homozygous and heterozygous familial hypercholesterolemia treated for one year were presented at the 2014 European Society of Cardiology Congress, according to an Isis Pharmaceuticals media release.
  • 29 Mar 2012 Interim results presented at the 16th International Symposium on Atherosclerosis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top